Literature DB >> 17493746

Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro.

Anske Van den Abbeele1, Veerle De Corte, Katrien Van Impe, Erik Bruyneel, Ciska Boucherie, Marc Bracke, Joël Vandekerckhove, Jan Gettemans.   

Abstract

Gelsolin and CapG are both actin binding proteins that modulate a variety of physiological processes by interacting differently with the actin cytoskeleton. Several studies suggest that overexpression of these proteins promotes invasion in vitro. In this study we explored the contribution of these proteins in human cancer cell invasion and motility. We show that down regulation of CapG or gelsolin in several types of cancer cells, including MDA-MB 231 and PC-3 cells, significantly reduces the invasive and motile properties of cells, as well as cell aggregation. These results point to a role for CapG and gelsolin as tumor activator.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493746     DOI: 10.1016/j.canlet.2007.03.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  38 in total

1.  The molecular chaperone CCT modulates the activity of the actin filament severing and capping protein gelsolin in vitro.

Authors:  Andreas Svanström; Julie Grantham
Journal:  Cell Stress Chaperones       Date:  2015-09-12       Impact factor: 3.667

2.  A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction.

Authors:  Anske Van den Abbeele; Sarah De Clercq; Ariane De Ganck; Veerle De Corte; Berlinda Van Loo; Sameh Hamdy Soror; Vasundara Srinivasan; Jan Steyaert; Joël Vandekerckhove; Jan Gettemans
Journal:  Cell Mol Life Sci       Date:  2010-02-07       Impact factor: 9.261

3.  Interactions between the actin filament capping and severing protein gelsolin and the molecular chaperone CCT: evidence for nonclassical substrate interactions.

Authors:  Karen I Brackley; Julie Grantham
Journal:  Cell Stress Chaperones       Date:  2010-10-02       Impact factor: 3.667

4.  A multiplex serum protein assay for determining the probability of colorectal cancer.

Authors:  Randall Brock; Bob Xiong; Lily Li; Ruth A Vanbogelen; Lori Christman
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

5.  Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation.

Authors:  Sarah De Clercq; Olivier Zwaenepoel; Evelien Martens; Joël Vandekerckhove; Aude Guillabert; Jan Gettemans
Journal:  Cell Mol Life Sci       Date:  2012-09-23       Impact factor: 9.261

6.  Epigenomic alterations in localized and advanced prostate cancer.

Authors:  Pei-Chun Lin; Eugenia G Giannopoulou; Kyung Park; Juan Miguel Mosquera; Andrea Sboner; Ashutosh K Tewari; Levi A Garraway; Himisha Beltran; Mark A Rubin; Olivier Elemento
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

7.  Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer.

Authors:  Carolina Panis; Luciana Pizzatti; Aedra Carla Bufalo; Ana Cristina Herrera; Vanessa Jacob Victorino; Rubens Cecchini; Eliana Abdelhay
Journal:  Tumour Biol       Date:  2015-10-15

Review 8.  Management of cytoskeleton architecture by molecular chaperones and immunophilins.

Authors:  Héctor R Quintá; Natalia M Galigniana; Alejandra G Erlejman; Mariana Lagadari; Graciela Piwien-Pilipuk; Mario D Galigniana
Journal:  Cell Signal       Date:  2011-08-12       Impact factor: 4.315

9.  Supervillin reorganizes the actin cytoskeleton and increases invadopodial efficiency.

Authors:  Jessica L Crowley; Tara C Smith; Zhiyou Fang; Norio Takizawa; Elizabeth J Luna
Journal:  Mol Biol Cell       Date:  2008-12-24       Impact factor: 4.138

10.  Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition.

Authors:  Emmanuelle Deniaud; Joël Baguet; Roxane Chalard; Bariza Blanquier; Lilia Brinza; Julien Meunier; Marie-Cécile Michallet; Aurélie Laugraud; Claudette Ah-Soon; Anne Wierinckx; Marc Castellazzi; Joël Lachuer; Christian Gautier; Jacqueline Marvel; Yann Leverrier
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.